Literature DB >> 22849875

Recurrent differentiated thyroid cancer.

Ashok R Shaha1.   

Abstract

OBJECTIVE: To discuss the risk of recurrence in patients with differentiated thyroid cancer and emphasize the importance of risk-group stratification.
METHODS: Common risk factors associated with recurrent thyroid cancer are outlined, and appropriate management strategies are reviewed.
RESULTS: The overall prognosis in patients with differentiated thyroid cancer is excellent. Factors associated with recurrent thyroid cancer include extrathyroidal extension of the primary tumor, bulky nodal metastatic lesions, macroscopic local invasion, and aggressive histologic subtypes. The locoregional recurrence and mortality are higher in patients with high-risk thyroid cancers. Patients initially presenting with locally aggressive and advanced thyroid cancer have a higher incidence of recurrent disease in the thyroid bed or nodal metastasis. These patients also have a high incidence of distant metastatic lesions. Locally recurrent thyroid cancer may be seen in more than 25% of patients with aggressive differentiated thyroid cancer. Recurrent disease in the thyroid bed can be a difficult problem to manage because of the proximity of the tumor to the recurrent laryngeal nerve, visceral structures in the central compartment, and occasional involvement of the trachea or larynx. External beam radiation therapy after surgical treatment may be important for better local control in the thyroid bed region, especially in patients with poorly differentiated histologic features. The role of additional radioiodine therapy remains undefined at this stage.
CONCLUSION: Management of patients with recurrent thyroid cancer necessitates a true multidisciplinary approach. These patients require close follow-up, with cross-sectional imaging and positron emission tomographic scanning in selected individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22849875     DOI: 10.4158/EP12047.CO

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  20 in total

1.  Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer.

Authors:  Sae Rom Chung; Jung Hwan Baek; Young Jun Choi; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2019-02-25       Impact factor: 5.315

2.  Central compartment revision surgery for persistent or recurrent thyroid carcinoma: analysis of survival and complication rate.

Authors:  Gabriele Molteni; Marco Bonali; Francesco Mattioli; Michael Ghirelli; Matteo Fermi; Gaetano Ferri; Malagoli Andrea; Livio Presutti
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-10       Impact factor: 2.503

3.  Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.

Authors:  Volkert B Wreesmann; Iain J Nixon; Michael Rivera; Nora Katabi; Frank Palmer; Ian Ganly; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Snehal G Patel; Ronald A Ghossein
Journal:  Thyroid       Date:  2015-03-31       Impact factor: 6.568

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 5.  The Emerging Role of EVA1A in Different Types of Cancers.

Authors:  Huijie Zhao; Huiyang Liu; Yihan Yang; Honggang Wang
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

6.  Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment-Oriented Lymph Node Resection.

Authors:  Carlos Gustavo Rivera-Robledo; David Velázquez-Fernández; Juan Pablo Pantoja; Mauricio Sierra; Bernardo Pérez-Enriquez; Raul Rivera-Moscoso; Mónica Chapa; Miguel F Herrera
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

7.  Evaluating the Time Interval for Presenting the Signs of Hypocalcaemia after Thyroidectomy.

Authors:  Mostafa Hosseini; Hamidreza Alizadeh Otaghvar; Adnan Tizmaghz; Ghazaal Shabestanipour; Parichehr Atef Vahid
Journal:  J Clin Diagn Res       Date:  2016-03-01

8.  An in vivo mouse model of metastatic human thyroid cancer.

Authors:  Lisa Zhang; Kelli Gaskins; Zhiya Yu; Yin Xiong; Maria J Merino; Electron Kebebew
Journal:  Thyroid       Date:  2014-03-10       Impact factor: 6.568

9.  Evaluating the effectiveness of targeted therapies for thyroid carcinoma: an updated meta-analysis.

Authors:  Shuai Lin; Jun Shen; Wanjun Zhao; Xiaofei Wang; Xiaoqing Wang; Jingqiang Zhu
Journal:  Ann Transl Med       Date:  2019-12

10.  Multi-gene assay and clinical characteristics research in papillary thyroid carcinoma.

Authors:  Chang Deng; Shan Li; Zhixin Yang; Yi Dou; Daixing Hu; Jiang Zhu; Denghui Wang; Xinliang Su
Journal:  Gland Surg       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.